Background Autoantibodies, especially antinuclear (ANAs) and anticytoplasmatic antibodies are essential diagnosing markers for several autoimmune diseases. ANA can sometimes also be found in organ-specific autoimmune diseases such as systemic lupus erythrmatosus. Fibromyalgia (FM) is a common disease characterized by chronic widespread pain and various manifestations. There has been reported high prevalence of psychosomatic distress, comorbidity, inflammatory autoimmune characteristics. Despite of its high prevalence, there is still no standardized laboratory test to suggest FMG or its severity.
Objectives Anti-dense fine speckled 70 (Anti-DFS70) antibodies were initially identified as an ANA from a patient with interstitial cystitis. Anti-DFS70 antibodies are found in 10% of healthy individuals, but only in a tiny population of with autoimmune rheumatic disease. These autoantibodies do not suggest any specific rheumatic disease. But there is no report in FM patients.
Methods It was based on the 80 fibromyalgia patients over the age of 20 who visited the two University hospitals from August 2008 to January 2013 and for the disease comparison group of 17 systemic lupus erythematosus patients, for the normal comparison group of 19 healthy individuals who have not been diagnosed systemic autoimmune rheumatic disease and without diabetes mellitus, hypertension, dyslipidemia, cerebral infarction, cardiovascular disease, infectious disease and chronic disease like cancer. Especially for physical measurement like height, weight and BMI and disease duration, tender point, FIQ (Fibromyalgia Impact Questionnaire), VAS (Visual Analogue Scale), somatic symptom and anti-DFS70 antibodies were measured and the American college of rheumatology 1990 classification criteria of FM was used to diagnose.
Results In this research, in the group with fibromyalgia patients group, systemic lupus erythematosus patients group and normal control group, they were evaluated for anti-DFS70 antibodies differences but statistically, between the three groups, there were high prevalence of anti-DFS70 antibodies in FM group. We checked relativity between anti-DFS70 antibodies and age, height, weight, BMI, disease duration, tender point, FIQ, VAS, and somatic symptom which were evaluated and statistically, they were confirmed to show the positive correlation between anti-DFS70 antibodies and VAS.
Conclusions The anti-DFS70 antibody is atypical pattern of ANA that shows availability in the diagnosing of the FM. Moreover, a large-scale research should be processed for the confirmation that reflected the positive correlation between anti-DFS70 antibodies and other clinical manifestations.
Disclosure of Interest None declared